EPIRUS Biopharmaceuticals, Inc.
EPRSQOTCHealthcare
$0.00
$-0.00(-99.00%)
Market Cap$1571
P/E Ratio—
52W High—
52W Low—
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EPRSQ · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2016Report Date: May 10, 2016EPS Actual
-$0.66
Est. -$0.54 · -22.2%
Revenue
—
Fiscal Period
Q2 FY2016
FY ends December
Report Date
May 10, 2016
After Market Close
▼ Miss EPS
EPRSQ reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2016 | May 10, 2016 | -$0.54 | -$0.66 | -22.2% | — | — | — |
| ▼ Q1 FY2016 | Mar 15, 2016 | -$0.56 | -$0.63 | -12.5% | — | — | — |
| ▼ Q4 FY2015 | Nov 16, 2015 | -$0.51 | -$0.59 | -15.7% | — | — | — |
| ▲ Q2 FY2015 | May 12, 2015 | -$0.42 | -$0.39 | +7.1% | — | — | — |
| ▲ Q1 FY2015 | Mar 23, 2015 | -$0.98 | -$0.80 | +18.4% | — | — | — |
| ▼ Q4 FY2014 | Nov 10, 2014 | -$0.43 | -$1.28 | -197.7% | — | — | — |
| ▼ Q2 FY2014 | May 9, 2014 | $2.00 | -$1.50 | -175.0% | — | — | — |
| ▼ Q1 FY2014 | Mar 13, 2014 | -$1.40 | -$2.90 | -107.1% | — | — | — |
Q2 FY2016
May 10, 2016Miss
EPS Actual
-$0.66
EPS Est.
-$0.54
EPS Surpr.
-22.2%
Revenue
—
Q1 FY2016
Mar 15, 2016Miss
EPS Actual
-$0.63
EPS Est.
-$0.56
EPS Surpr.
-12.5%
Revenue
—
Q4 FY2015
Nov 16, 2015Miss
EPS Actual
-$0.59
EPS Est.
-$0.51
EPS Surpr.
-15.7%
Revenue
—
Q2 FY2015
May 12, 2015Beat
EPS Actual
-$0.39
EPS Est.
-$0.42
EPS Surpr.
+7.1%
Revenue
—
Q1 FY2015
Mar 23, 2015Beat
EPS Actual
-$0.80
EPS Est.
-$0.98
EPS Surpr.
+18.4%
Revenue
—
Q4 FY2014
Nov 10, 2014Miss
EPS Actual
-$1.28
EPS Est.
-$0.43
EPS Surpr.
-197.7%
Revenue
—
Q2 FY2014
May 9, 2014Miss
EPS Actual
-$1.50
EPS Est.
$2.00
EPS Surpr.
-175.0%
Revenue
—
Q1 FY2014
Mar 13, 2014Miss
EPS Actual
-$2.90
EPS Est.
-$1.40
EPS Surpr.
-107.1%
Revenue
—
No analyst estimates available for EPRSQ.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2016 | May 10, 2016 | -22.2% | $2.72 | $1.08 | -60.29% |
| ▼ Q1 FY2016 | Mar 15, 2016 | -12.5% | $3.14 | $2.80 | -10.83% |
| ▼ Q4 FY2015 | Nov 16, 2015 | -15.7% | $5.18 | $4.96 | -4.25% |
| ▲ Q2 FY2015 | May 12, 2015 | +7.1% | $6.95 | $6.23 | -10.36% |
| ▲ Q1 FY2015 | Mar 23, 2015 | +18.4% | $9.30 | $8.76 | -5.81% |
| ▼ Q4 FY2014 | Nov 10, 2014 | -197.7% | $4.51 | $4.57 | +1.33% |
| ▼ Q2 FY2014 | May 9, 2014 | -175.0% | $9.60 | $9.00 | -6.25% |
| ▼ Q1 FY2014 | Mar 13, 2014 | -107.1% | $13.50 | $13.20 | -2.22% |
Q2 FY2016-60.29%
Report Date
May 10, 2016
EPS Beat/Miss
-22.2%
Price Before
$2.72
Price After
$1.08
Q1 FY2016-10.83%
Report Date
Mar 15, 2016
EPS Beat/Miss
-12.5%
Price Before
$3.14
Price After
$2.80
Q4 FY2015-4.25%
Report Date
Nov 16, 2015
EPS Beat/Miss
-15.7%
Price Before
$5.18
Price After
$4.96
Q2 FY2015-10.36%
Report Date
May 12, 2015
EPS Beat/Miss
+7.1%
Price Before
$6.95
Price After
$6.23
Q1 FY2015-5.81%
Report Date
Mar 23, 2015
EPS Beat/Miss
+18.4%
Price Before
$9.30
Price After
$8.76
Q4 FY2014+1.33%
Report Date
Nov 10, 2014
EPS Beat/Miss
-197.7%
Price Before
$4.51
Price After
$4.57
Q2 FY2014-6.25%
Report Date
May 9, 2014
EPS Beat/Miss
-175.0%
Price Before
$9.60
Price After
$9.00
Q1 FY2014-2.22%
Report Date
Mar 13, 2014
EPS Beat/Miss
-107.1%
Price Before
$13.50
Price After
$13.20
Avg Beat Reaction-8.08%
Avg Miss Reaction-13.75%
Beat Rate2 / 8 quarters
Largest Move-60.29% (Q2 FY2016)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EPRSQ ends December
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) most recently reported earnings on May 10, 2016 for Q2 FY2016, posting EPS of $-0.66 — missing the analyst consensus of $-0.54 by -22.2%. The next EPRSQ earnings date is expected around September 1, 2026.
Each quarter, investors track EPRSQ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EPRSQ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EPRSQ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EPRSQ earnings · 5 questionsEPIRUS Biopharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. EPRSQ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EPRSQ historically reports after market close (AMC).
EPRSQ earnings datewhen is EPRSQ earningsEPRSQ next earnings datewhen does EPRSQ report earningsEPRSQ earnings calendar
▸ Source: FMP · EPIRUS Biopharmaceuticals, Inc. SEC filings · US GAAP · EPIRUS Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026